Barrachina Jordi, Margarit César, Andreu Blanca, Zandonai Thomas, Ballester Pura, Muriel Javier, Cutillas Esperanza, Peiró Ana M
Neuropharmacology on Pain and Functional Diversity (NED), Alicante Institute for Health and Biomedical Research (ISABIAL) Alicante, Spain.
Pain Unit, Department of Health of Alicante-General Hospital, Alicante, Spain.
Acta Pharm. 2022 Oct 18;72(4):529-545. doi: 10.2478/acph-2022-0035. Print 2022 Dec 1.
A good therapeutic alliance is relevant for healthcare providers exposed to patients' suffering, especially since patients and physicians may understand the painful experience differently. Our aim was to explore the impact of therapeutic alliance on analgesic outcomes in a real-world interdisciplinary pain unit (PU). A cross-sectional observational study was conducted on outpatients ( = 69) using opioids on a long-term basis for the treatment of chronic non-cancer pain, where clinical pharmacologists and pharmacists advised patients about their opioid treatment. Responses to the patient-doctor relationship questionnaire (PDRQ), sociodemographic and clinical information (pain level, quality of life and hospital use) were collected, whereas pharmacology data (analgesic prescription, adverse events, and compliance) were obtained from electronic health records. Patients were predominantly middle-aged (75 % women, 72 % retired), experiencing moderate pain (VAS 40-70 mm) on average, and under a high morphine equianalgesic dosage (95 ± 88 mg per day, mainly tapentadol or fentanyl). Patients with better PDRQ outcomes, and therefore better therapeutic alliance, showed lower pain intensity than patients with worse PDRQ outcomes (pain intensity: high scores 60 ± 47 mm and medium scores 60 ± 45 mm . low scores 80 ± 75 mm, < 0.01). Along with this, pain intensity was lower when patients affirmed that, thanks to the health-care providers, they "gained new insight", "felt better", or "felt content with their doctor's treatment". What´s more, patients who affirmed "I benefit from the treatment" experienced increased pain relief (benefit 40 ± 30 . non-benefit 19 ± 26 mm, = 0.010) and improved quality of life (benefit 33 ± 25 . non-benefit 18 ± 16 mm, = 0.031). However, there was a percentage of patients who did not fully understand the provided information, which is something to be taken into account to improve in clinical routine. Therapeutic alliance supported by pharmacist experts on pain management can be an effective strategy to improve analgesic outcomes. Further efforts are needed to improve communication strategies for pain management. Future directions of research should include the analysis of the role of the pharmacist in poly-professional consultations as related to the advice of patients about their medication, and the mutual trust with the patients.
良好的治疗联盟对于接触患者痛苦的医疗服务提供者来说至关重要,尤其是因为患者和医生对痛苦经历的理解可能不同。我们的目的是探讨治疗联盟对现实世界中跨学科疼痛单元(PU)镇痛效果的影响。对69名长期使用阿片类药物治疗慢性非癌性疼痛的门诊患者进行了一项横断面观察性研究,临床药理学家和药剂师就其阿片类药物治疗向患者提供建议。收集了患者对医患关系问卷(PDRQ)的回答、社会人口学和临床信息(疼痛程度、生活质量和住院情况),而药理学数据(镇痛处方、不良事件和依从性)则从电子健康记录中获取。患者主要为中年(75%为女性,72%已退休),平均经历中度疼痛(视觉模拟评分40 - 70毫米),且处于高吗啡等效镇痛剂量(每天95±88毫克,主要为曲马多或芬太尼)。PDRQ结果较好、因此治疗联盟较好的患者,其疼痛强度低于PDRQ结果较差的患者(疼痛强度:高分者60±47毫米,中等分数者60±45毫米,低分者80±75毫米,P<0.01)。与此同时,当患者肯定由于医疗服务提供者他们“获得了新的认识”、“感觉好多了”或“对医生的治疗感到满意”时,疼痛强度较低。此外,肯定“我从治疗中受益”的患者疼痛缓解增加(受益组40±30,非受益组19±26毫米,P = 0.010)且生活质量改善(受益组33±25,非受益组18±16毫米,P = 0.031)。然而,有一定比例的患者没有完全理解所提供的信息,这在临床常规中需要加以考虑。由药剂师专家支持的疼痛管理治疗联盟可能是改善镇痛效果的有效策略。需要进一步努力改进疼痛管理的沟通策略。未来的研究方向应包括分析药剂师在多专业会诊中与患者药物建议相关的作用,以及与患者的相互信任。